The Effect of Labisia pumila var. alata on Postmenopausal Women: A Pilot Study

Table 3

Cardiovascular risk factors and hormonal changes after 6-month followup trial with placebo and Labisia pumila at 280 mg.

Study variables	Trial groups^†			𝑃 value^‡
	Placebo (𝑛=34)	Labisia (𝑛=29)	Adjusted mean difference (95% CI)
Cardiovascular disease risk factors
Total cholesterol (mmol/L)	5.5 (5.2, 5.9)	5.0 (4.6, 5.4)	0.5 (−0.06, 1.04)	0.082
Triglycerides (mmol/L)	1.9 (1.6, 2.2)	1.4 (1.1, 1.7)	0.5 (0.02, 0.89)	0.042
Fasting glucose (mmol/L)	6.3 (5.8, 6.8)	5.6 (5.1, 6.2)	0.7 (−0.06, 1.38)	0.073
Diastolic BP (mm Hg)	81.2 (78.3, 84.1)	82.1 (78.9, 85.2)	0.9 (−3.4, 5.2)	0.686
Systolic BP (mm Hg)	125.8 (120.9, 130.7)	127.5 (122.1, 132.8)	1.7 (−5.6, 9.0)	0.643
Female hormones (IU)
FSH	36.3 (29.7, 42.8)	38.4 (31.3, 45.5)	2.11 (−7.62, 11.84)	0.665
LH	26.2 (21.8, 30.5)	24.4 (19.9, 29.0)	1.75 (−4.59, 8.08)	0.583
Estrogen	37.5 (31.4, 43.5)	33.5 (26.7, 40.3)	3.94 (−5.23, 13.10)	0.393

Abbreviations: LH: luteinizing hormone; FSH: follicle stimulating hormone; BP: blood pressure.
^†Values at 6-month followup are expressed as adjusted means (95% confidence interval, CI) and are adjusted for baseline values, age, BMI, and duration of menopause.
^‡Determined by analysis of covariance (ANCOVA); 𝑃 value < 0.05 is considered significant.